Synaffix inks $246m deal with ProfoundBio
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2166 entries already.
Entries by Thomas Gabrielczyk
BioNTech takes over cancer immunotherapy platform
Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Nanosyrinx raises £6.2m to validate drug delivery platform
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
Unilever licences Arzeda Inc.s enzyme technology
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Bio-Me raises NOK10m
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Drug repurposing trends shorten timelines
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Novalis Biotech closes biotech fund at €25m
Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups.
Cellink AB to take-over Discover Echo Inc
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Thermo Scientific HyPerforma GXCore Bioprocess Controller
The Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.
Rheincell set to be acquired by Catalent
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.